Dragonfly, Bristol Myers Squibb to develop immunotherapies

By The Science Advisory Board staff writers

July 6, 2020 -- Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple sclerosis and neuroinflammatory targets.

Under the agreement, Bristol Myers Squibb will have the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary Trinket technology platform. Bristol Myers Squibb will pay Dragonfly a $55 million upfront payment, and Dragonfly will be eligible for additional development, regulatory, and milestone payments, as well as royalties on sales of approved product sales.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.